These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 27899158)

  • 1. High rate of complete responses to immune checkpoint inhibitors in patients with relapsed or refractory Hodgkin lymphoma previously exposed to epigenetic therapy.
    Falchi L; Sawas A; Deng C; Amengual JE; Colbourn DS; Lichtenstein EA; Khan KA; Schwartz LH; O'Connor OA
    J Hematol Oncol; 2016 Nov; 9(1):132. PubMed ID: 27899158
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FDA Approval Summary: Nivolumab for the Treatment of Relapsed or Progressive Classical Hodgkin Lymphoma.
    Kasamon YL; de Claro RA; Wang Y; Shen YL; Farrell AT; Pazdur R
    Oncologist; 2017 May; 22(5):585-591. PubMed ID: 28438889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation.
    Armand P; Chen YB; Redd RA; Joyce RM; Bsat J; Jeter E; Merryman RW; Coleman KC; Dahi PB; Nieto Y; LaCasce AS; Fisher DC; Ng SY; Odejide OO; Freedman AS; Kim AI; Crombie JL; Jacobson CA; Jacobsen ED; Wong JL; Patel SS; Ritz J; Rodig SJ; Shipp MA; Herrera AF
    Blood; 2019 Jul; 134(1):22-29. PubMed ID: 30952672
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial.
    Armand P; Engert A; Younes A; Fanale M; Santoro A; Zinzani PL; Timmerman JM; Collins GP; Ramchandren R; Cohen JB; De Boer JP; Kuruvilla J; Savage KJ; Trneny M; Shipp MA; Kato K; Sumbul A; Farsaci B; Ansell SM
    J Clin Oncol; 2018 May; 36(14):1428-1439. PubMed ID: 29584546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-dose pembrolizumab for relapsed/refractory Hodgkin lymphoma: high efficacy with minimal toxicity.
    Chan TS; Luk TH; Lau JS; Khong PL; Kwong YL
    Ann Hematol; 2017 Apr; 96(4):647-651. PubMed ID: 28138786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune checkpoint inhibitors in combination with radiotherapy as salvage treatment for relapsed/refractory classical Hodgkin lymphoma: A retrospective analysis in 12 patients.
    Lucchini E; Rusconi C; Levis M; Ricci F; Santoro A; Ricardi U; Volpetti S; Matrone F; di Russo A; Caizzi M; Schiattarella A; Zaja F
    Hematol Rep; 2021 Jun; 13(2):9080. PubMed ID: 34221295
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087.
    Chen R; Zinzani PL; Lee HJ; Armand P; Johnson NA; Brice P; Radford J; Ribrag V; Molin D; Vassilakopoulos TP; Tomita A; von Tresckow B; Shipp MA; Lin J; Kim E; Nahar A; Balakumaran A; Moskowitz CH
    Blood; 2019 Oct; 134(14):1144-1153. PubMed ID: 31409671
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radiotherapy in combination with nivolumab for relapsed/refractory classical Hodgkin lymphoma: About two cases.
    de Forceville L; Deau-Fischer B; Franchi P; Arsène-Henry A; Cassou Mounat T; Bouscary D; Kirova YM
    Cancer Radiother; 2019 Jun; 23(3):232-239. PubMed ID: 31147173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical, Imaging Findings, Responses, and Outcomes of Patients With Classical Hodgkin Lymphoma and Non-Hodgkin Lymphoma Undergoing Immune Checkpoint Inhibitor Therapy: A Single-Institution Experience.
    Liput J; Guler E; Smith DA; Tirumani SH; Hoimes C; Caimi PF; Ramaiya NH
    J Comput Assist Tomogr; 2020; 44(4):619-626. PubMed ID: 32558769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Addition of Low-Dose Decitabine to Anti-PD-1 Antibody Camrelizumab in Relapsed/Refractory Classical Hodgkin Lymphoma.
    Nie J; Wang C; Liu Y; Yang Q; Mei Q; Dong L; Li X; Liu J; Ku W; Zhang Y; Chen M; An X; Shi L; Brock MV; Bai J; Han W
    J Clin Oncol; 2019 Jun; 37(17):1479-1489. PubMed ID: 31039052
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Where Do the New Drugs Fit in for Relapsed/Refractory Hodgkin Lymphoma?
    Khan N; Moskowitz AJ
    Curr Hematol Malig Rep; 2017 Jun; 12(3):227-233. PubMed ID: 28488185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term survival outcomes of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma: a systematic review and meta-analysis.
    Wang Z; Sun K; Zhu ZM; Zhang P; Yang J; Yang SW; Zheng MQ
    Eur Rev Med Pharmacol Sci; 2021 Apr; 25(7):2941-2948. PubMed ID: 33877657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Back to life with checkpoint inhibitors in Hodgkin lymphoma.
    Dada R; Zekri J
    J Oncol Pharm Pract; 2018 Mar; 24(2):139-142. PubMed ID: 28597713
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed/refractory classical Hodgkin lymphoma.
    Armand P; Zinzani PL; Lee HJ; Johnson NA; Brice P; Radford J; Ribrag V; Molin D; Vassilakopoulos TP; Tomita A; von Tresckow B; Shipp MA; Herrera AF; Lin J; Kim E; Chakraborty S; Marinello P; Moskowitz CH
    Blood; 2023 Sep; 142(10):878-886. PubMed ID: 37319435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-dose pembrolizumab induced remission in patients with refractory classical Hodgkin lymphoma.
    Kwong YL; Lopes D; Khong PL
    Br J Haematol; 2017 Jan; 176(1):131-132. PubMed ID: 26773814
    [No Abstract]   [Full Text] [Related]  

  • 16. Three-year outcomes with brentuximab vedotin plus bendamustine as first salvage therapy in relapsed or refractory Hodgkin lymphoma.
    LaCasce AS; Bociek RG; Sawas A; Caimi P; Agura E; Matous J; Ansell SM; Crosswell HE; Islas-Ohlmayer M; Behler C; Cheung E; Forero-Torres A; Vose J; O'Connor OA; Josephson N; Wang Y; Advani R
    Br J Haematol; 2020 May; 189(3):e86-e90. PubMed ID: 32048731
    [No Abstract]   [Full Text] [Related]  

  • 17. Brentuximab vedotin as a salvage treatment for relapsed and refractory Hodgkin lymphoma patients in Taiwan.
    Tien FM; Tsai CH; Liu JH; Lin CT
    J Formos Med Assoc; 2019 Oct; 118(10):1466-1470. PubMed ID: 31337522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes and Toxicities of Programmed Death-1 (PD-1) Inhibitors in Hodgkin Lymphoma Patients in the United States: A Real-World, Multicenter Retrospective Analysis.
    Bair SM; Strelec LE; Feldman TA; Ahmed G; Armand P; Shah NN; Singavi AN; Reddy N; Khan N; Andreadis C; Vu K; Huntington SF; Giri S; Ujjani C; Howlett C; Faheem M; Youngman MR; Nasta SD; Landsburg DJ; Schuster SJ; Svoboda J
    Oncologist; 2019 Jul; 24(7):955-962. PubMed ID: 30568021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful reversal of severe liver function impairment with Brentuximab vedotin in multiply relapsed/refractory classical Hodgkin lymphoma.
    Spathas N; Belia M; Giannikos T; Arapaki M; Efstathopoulou M; Tsourouflis G; Gainaru G; Asimakopoulos J; Tsaftaridis P; K Angelopoulou M; Plata E; Konstantopoulos K; P Vassilakopoulos T
    J BUON; 2019; 24(6):2483-2489. PubMed ID: 31983123
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.
    Gravanis I; Tzogani K; van Hennik P; de Graeff P; Schmitt P; Mueller-Berghaus J; Salmonson T; Gisselbrecht C; Laane E; Bergmann L; Pignatti F
    Oncologist; 2016 Jan; 21(1):102-9. PubMed ID: 26621039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.